Ara
Toplam kayıt 42, listelenen: 31-40
Vibration-controlled transient elastography for non-invasive screening of liver fibrosis and steatosis in Turkish patients with A cross-sectional
(Kare Publishing, 2024)
Background and Aim: The prevalence of fibrosis and steatosis in patients with psoriasis, as determined by vibration-controlled transient elastography (VCTE), has not been evaluated in Turkiye to date. The present cross-sectional ...
Predicting fibrosis progression in non-alcoholic fatty liver disease patients using the FAST Score: A paired biopsy study
(Kare Publishing, 2024)
Background and Aim: This study aimed to investigate the predictive value of various non-invasive scores for identifying the progression of hepatic fibrosis over time in patients with Non-Alcoholic Fatty Liver Disease ...
Addressing the looming epidemic of metabolic dysfunction-associated steatotic liver disease in Pakistan: A call for action
(Kare Publishing, 2024)
The term metabolic dysfunction-associated steatotic liver disease
(MASLD), which evolved from its predecessor, nonalcoholic fatty liver
disease (NAFLD),[1]
Association of metabolic dysfunction-associated fatty liver disease with cognitive impairment and all-cause dementia: A comprehensive review
(AVES, 2024)
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a significant public health concern, affecting one-third of the global population and posing a risk for progressive liver disease. MAFLD is characterized by ...
The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement
(Wiley, 2024)
Background:Following the adoption of new nomenclature for steatotic liver disease, we aimed to build consensus on the use of International Classification of Diseases codes and recommendations for future research and ...
Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa
(Wiley, 2024)
Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is common and closely associated with type 2 diabetes (T2D). We assessed ...
Deciphering the implications of MAFLD and MASLD definitions in the NAFLD population: Results from a single-center biopsy study
(Wolters Kluwer Medknow Publications, 2024)
To the Editor: The nomenclature for steatotic liver disease has been a topic of debate since 2020. The conventional expression, non-alcoholic fatty liver disease (NAFLD), was introduced in 1980 to describe the occurrence ...
A phase 3 trial of seladelpar in primary biliary cholangitis
(Massachussetts Medical Society, 2024)
Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential benefits. METHODS In this phase 3, 12-month, double-blind, ...
Prevalence, determinants, and fibrosis risk stratification of metabolic-associated fatty liver disease in a Turkish primary care setting: A retrospective study
(Kare Publishing, 2023)
Background and Aim: Metabolic-associated fatty liver disease (MAFLD) is a condition that frequently goes unnoticed as it typically remains asymptomatic until progressing to an advanced stage. As a result, it is essential ...
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
(Elsevier, 2023)
The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient ...